Nucleic acid aptamers
The present invention relates to optimized aptamers and methods of using these aptamers.
1. A nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-1 (SEQ ID NO:2322), aptamer-35 (SEQ ID NO:2356), aptamer-41 (SEQ ID NO:2362) or aptamer-51 (SEQ ID NO:2372).
2. The nucleic acid molecule of claim 1 , wherein the aptamer is aptamer-1 (SEQ ID NO:2322).
3. The nucleic acid molecule of claim 1 , wherein the aptamer is aptamer-35 (SEQ ID NO:2356).
4. The nucleic acid molecule of claim 1 , wherein the aptamer is aptamer-41 (SEQ ID NO:2362).
5. The nucleic acid molecule of claim 1 , wherein the aptamer is aptamer-51 (SEQ ID NO:2372).
6. The nucleic acid molecule of claim 1 , wherein the nucleotides are RNA.
7. The nucleic acid molecule of claim 6 , wherein the RNA includes a modified nucleotide.
8. The nucleic acid molecule of claim 7 , wherein the RNA is chemically modified (2′-fluoropyridines).
9. A conjugate comprising the nucleic acid molecule of claim 1 linked to a therapeutic or diagnostic molecule.
10. The conjugate of claim 9 , wherein the therapeutic molecule is an RNAi molecule.
11. The conjugate of claim 10 , wherein the RNAi molecule is an siRNA molecule or an miRNA molecule.
12. The conjugate of claim 11 , wherein the siRNA specifically targets Nx1 NADPH oxidase.
13. A method for delivering a therapeutic or diagnostic molecule to a vascular smooth muscle cell, comprising contacting the cell with the conjugate of claim 9 .
14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and
(i) a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-1 (SEQ ID NO:2322), aptamer-35 (SEQ ID NO:2356), aptamer-41 (SEQ ID NO:2362) or aptamer-51 (SEQ ID NO:2372); or
(ii) a conjugate comprising a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-1 (SEQ ID NO:2322), aptamer-35 (SEQ ID NO:2356), aptamer-41 (SEQ ID NO:2362) or aptamer-51 (SEQ ID NO:2372) operably linked to a therapeutic or diagnostic molecule.
15. An article of manufacture comprising a solid substrate coated with the molecule of claim 1 .
16. The article of claim 15 , wherein the solid substrate is a stent, catheter, a catheter hub, a catheter port, or a non-degradable implant.